Purpose

Patients with type 1 diabetes type 1 (DM1) have increased risk of death due to heart disease and stroke. These cardiovascular conditions (CVD) are the leading cause of death in patients with DM1 younger than 40 years of age and up to 35% of all persons with DM1 will die before age 55 from CVD. Strategies are needed to help identify adolescents with DM1 at risk for CVD so that interventions to prevent heart disease and stroke can be undertaken.

Conditions

Eligibility

Eligible Ages
Between 12 Years and 21 Years
Eligible Genders
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

Diabetes type 1 or Healthy

Exclusion Criteria

Taking medications that lower cholesterol Duration of type 1 diabetes < 1 year.

Study Design

Phase
Study Type
Observational
Observational Model
Case-Control
Time Perspective
Cross-Sectional

Arm Groups

ArmDescriptionAssigned Intervention
Diabetes Children with diabetes type 1 , 12-21 years old
Healthy Healthy children 12-21 years old

Recruiting Locations

Georgetown-Howard Universities Center
Washington, District of Columbia 20007
Contact:
Stephanie Gubb
202-444-1210

More Details

NCT ID
NCT02275091
Status
Recruiting
Sponsor
Georgetown University

Study Contact

Evgenia Gourgari, MD
2024441210

Detailed Description

Patients with type 1 diabetes and healthy controls will have evaluation of their lipid profile. Arterial stiffness, heart rate variability and adiposity measurements will be done in patients with type 1 diabetes and healthy controls. Blood pressure and heart rate will be recorded. 50 ml of urine will be collected from patients and controls.

All studies will be performed as a single outpatient visit at Georgetown University.

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.